Prognostic Significance of Programmed Cell Death-Ligand 1 Expression in Tobacco Associated Oral Squamous Cell Carcinoma: An Immunohistochemical Based Cross-Sectional Study

IF 2.7 3区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of Oral Pathology & Medicine Pub Date : 2024-10-07 DOI:10.1111/jop.13584

Naga Naveena N., Sweta Mohanty, Surya Narayan Das, Rachna Rath, Sri Priya Narayanan

{"title":"Prognostic Significance of Programmed Cell Death-Ligand 1 Expression in Tobacco Associated Oral Squamous Cell Carcinoma: An Immunohistochemical Based Cross-Sectional Study","authors":"Naga Naveena N., Sweta Mohanty, Surya Narayan Das, Rachna Rath, Sri Priya Narayanan","doi":"10.1111/jop.13584","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Advancements in immuno-oncology have dramatically transformed cancer treatment. Immunotherapy, targeting immune check point proteins, notably Programmed cell death ligand 1 (PD-L1) and its receptor Programmed Cell Death-1 (PD-1) which modulate the activity of immune response in Head and Neck squamous cell carcinomas (HNSCC), is an area of much research. The immunohistochemical expression of PD-L1 in cancer cells has been proposed as a predictive biomarker for selecting candidates for immunotherapy. Thus, the present study was undertaken to study the expression of PD-L1 in the primary tumour cells and evaluate its correlation with various clinicopathological parameters and prognosis in tobacco associated oral squamous cell carcinomas (OSCC).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Expression of PD-L1 was investigated in 75 surgically resected cases of OSCC by immunohistochemistry and its association with different clinicopathological features and prognosis was analysed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>PD-L1 protein was detected in 68% (51 cases) of cases. Tumour stage (<i>p</i> = 0.04), lymph node (LN) metastasis (<i>p</i> < 0.01) and moderate to marked tumour infiltrating lymphocytes (TILs) (<i>p</i> < 0.05), significantly correlated with the PD-L1 expression in the primary tumour. PD-L1 expression did not show a significant association with overall survival (OS) rate, however, patients with positive PD-L1 expression showed a poorer survival rate. Patients exhibiting nodal positivity had the worst prognosis (<i>p</i> < 0.005).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>These data demonstrated a significant association of ≥ 5% PD-L1 expression in the primary tumour and the presence of LN metastasis, moderate to marked TILs and advancing tumour stage, thus, making it a plausible immunotherapeutic target molecule in OSCC patients.</p>\n </section>\n </div>","PeriodicalId":16588,"journal":{"name":"Journal of Oral Pathology & Medicine","volume":"53 10","pages":"648-656"},"PeriodicalIF":2.7000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oral Pathology & Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jop.13584","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Advancements in immuno-oncology have dramatically transformed cancer treatment. Immunotherapy, targeting immune check point proteins, notably Programmed cell death ligand 1 (PD-L1) and its receptor Programmed Cell Death-1 (PD-1) which modulate the activity of immune response in Head and Neck squamous cell carcinomas (HNSCC), is an area of much research. The immunohistochemical expression of PD-L1 in cancer cells has been proposed as a predictive biomarker for selecting candidates for immunotherapy. Thus, the present study was undertaken to study the expression of PD-L1 in the primary tumour cells and evaluate its correlation with various clinicopathological parameters and prognosis in tobacco associated oral squamous cell carcinomas (OSCC).

Methods

Expression of PD-L1 was investigated in 75 surgically resected cases of OSCC by immunohistochemistry and its association with different clinicopathological features and prognosis was analysed.

Results

PD-L1 protein was detected in 68% (51 cases) of cases. Tumour stage (p = 0.04), lymph node (LN) metastasis (p < 0.01) and moderate to marked tumour infiltrating lymphocytes (TILs) (p < 0.05), significantly correlated with the PD-L1 expression in the primary tumour. PD-L1 expression did not show a significant association with overall survival (OS) rate, however, patients with positive PD-L1 expression showed a poorer survival rate. Patients exhibiting nodal positivity had the worst prognosis (p < 0.005).

Conclusion

These data demonstrated a significant association of ≥ 5% PD-L1 expression in the primary tumour and the presence of LN metastasis, moderate to marked TILs and advancing tumour stage, thus, making it a plausible immunotherapeutic target molecule in OSCC patients.

查看原文本刊更多论文

烟草相关口腔鳞状细胞癌中程序性细胞死亡配体 1 表达的预后意义：一项基于免疫组化的横断面研究

背景：免疫肿瘤学的进步极大地改变了癌症治疗。针对免疫检查点蛋白，特别是调节头颈部鳞状细胞癌（HNSCC）免疫反应活性的程序性细胞死亡配体 1（PD-L1）及其受体程序性细胞死亡-1（PD-1）的免疫疗法是一个备受关注的研究领域。PD-L1 在癌细胞中的免疫组化表达被认为是选择免疫疗法候选者的预测性生物标志物。因此，本研究旨在研究原发肿瘤细胞中 PD-L1 的表达，并评估其与烟草相关口腔鳞状细胞癌（OSCC）的各种临床病理参数和预后的相关性：方法：采用免疫组化方法研究75例手术切除的OSCC中PD-L1的表达情况，并分析其与不同临床病理特征和预后的关系：结果：68%的病例（51例）检测到PD-L1蛋白。肿瘤分期（p = 0.04）、淋巴结（LN）转移（p 结论：PD-L1 蛋白与肿瘤分期、淋巴结转移和预后密切相关：这些数据表明，原发肿瘤中 PD-L1 表达≥5%与淋巴结转移、中度至明显的 TILs 和肿瘤分期进展存在显著关联，因此，PD-L1 是 OSCC 患者中一个可信的免疫治疗靶分子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Oral Pathology & Medicine 医学-病理学

CiteScore

5.90

自引率

6.10%

发文量

121

审稿时长

4-8 weeks

期刊介绍： The aim of the Journal of Oral Pathology & Medicine is to publish manuscripts of high scientific quality representing original clinical, diagnostic or experimental work in oral pathology and oral medicine. Papers advancing the science or practice of these disciplines will be welcomed, especially those which bring new knowledge and observations from the application of techniques within the spheres of light and electron microscopy, tissue and organ culture, immunology, histochemistry and immunocytochemistry, microbiology, genetics and biochemistry.